TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15322598
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ACEI and digoxin
Study: 9290119
Drug: Beta-carotene (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (30 mg/day) for three months
Study: 31603268
Drug: Intravenous dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dopamine (2 µg kg‐1 min‐1)
Study: 31603268
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline and D2‐receptor antagonist (20 mg oral metoclopramide)
Study: 31603268
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline and placebo pill
Study: 22122912
Drug: Carer Assisted
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carer Assisted Adherence Therapy (CAAT)
Study: 16505207
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II receptor blocker (ARB; candesartan 8 mg/day, n=11 or valsartan 80 mg/day, n=22)
Study: 16505207
Drug: Trichlormethiazide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trichlormethiazide (2 mg/day)
Study: 8875516
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion (group AA)
Study: 8875516
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion (group ALAGLN)
Study: 1863724
Drug: DDAVP (desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDAVP (desmopressin acetate) 0.3 microgram/kg administered over 5 minutes (group 2)
Study: 6395275
Drug: Cefonicid (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefonicid (1,000 mg once daily, with some patients receiving 500 mg)
Study: 6395275
Drug: Cefamandole (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole (1,000 mg every 6 hours)
Study: 30802720
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg of spearmint extract (PSE)
Study: 25808690
Drug: Minimized collar
Normalized name: homatropine hydrobromide Ophthalmic Solution [Minims Homatropine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimized collar (MC) implant at crestal bone level
Study: 25808690
Drug: Long collar
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long collar (LC) implant 2.5 mm supracrestal
Study: 22503786
Drug: Nebulised frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised frusemide (40 mg, 4 ml)
Study: 19876062
Drug: Melatonin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (5 mg before sleep)
Study: 12118494
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg droperidol
Study: 12118494
Drug: 5.0 mg
Normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg metoclopramide
Study: 7114936
Drug: Limb-sparing resection
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limb-sparing resection plus adjuvant radiation therapy
Study: 31075187
Drug: Evobrutinib 25
Normalized name: Evobrutinib
DrugBank: Evobrutinib (DB15170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evobrutinib 25 mg once daily
Study: 31075187
Drug: Evobrutinib 75
Normalized name: Evobrutinib
DrugBank: Evobrutinib (DB15170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evobrutinib 75 mg once daily
Study: 31075187
Drug: Evobrutinib 75
Normalized name: Evobrutinib
DrugBank: Evobrutinib (DB15170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evobrutinib 75 mg twice daily
Study: 24643924
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (0.2 mg) with 0.5% hyperbaric bupivacaine
Study: 8469820
Drug: Dopamine (DOP2)
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dopamine (DOP2) at a dose sufficient to induce a similar rise in MAP as DBT1
Study: 8469820
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion (NS1 and NS2)
Study: 3081208
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose concentration at 6.3 mmol/l (113.5 mg/100 ml)
Study: 3081208
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose concentration at 2.9 mmol/l (52.3 mg/100 ml)
Study: 3081208
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose concentration at 1.8 mmol/l (32.4 mg/100 ml)
Study: 3081208
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose concentration at 6.1 mmol/l (109.9 mg/100 ml) after intravenous glucose
Study: 3081208
Drug: Period C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period C (1.8 mmol/l)
Study: 3081208
Drug: Period A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period A (6.3 mmol/l) and Period B (2.9 mmol/l)
Study: 3081208
Drug: Period D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period D (6.1 mmol/l)
Study: 3169372
Drug: Doxofylline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxofylline (200 mg intravenously over 15 min)
Study: 28497402
Drug: Resection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resection of the primary tumor plus systemic chemotherapy after surgery
Study: 26399752
Drug: NIPPV (subgroup
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIPPV (subgroup with surfactant therapy)
Study: 26399752
Drug: NCPAP (subgroup
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCPAP (subgroup with surfactant therapy)
Study: 23433347
Drug: Diabetes specialist/educator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes specialist/educator consultation support (active for 2 months, passive for 10 months) and community retail pharmacist support (1-hour insulin-initiation session)
Study: 21584948
Drug: Arformoterol (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arformoterol (7.5 µg/dose)
Study: 21584948
Drug: Arformoterol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arformoterol (15 µg/dose)
Study: 21584948
Drug: Levalbuterol (0.63
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levalbuterol (0.63 mg/dose)
Study: 16585472
Drug: Behavioral Treatment
Normalized name: AspyreRx Digital Behavioral Therapeutic Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Treatment for Substance Abuse in Severe and Persistent Mental Illness (BTSAS)
Study: 16585472
Drug: Supportive Treatment
Normalized name: Performax Salt Supportive Cream Base for Compounding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive Treatment for Addiction Recovery (STAR)
Study: 14689372
Drug: Intravenous angiotensin
Normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous angiotensin II infusion (0-512 ng/minute) during placebo therapy
Study: 14689372
Drug: Intravenous angiotensin
Normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous angiotensin II infusion during telmisartan therapy (40-80 mg/day)
Study: 14689372
Drug: Telmisartan therapy
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan therapy (40-80 mg/day)
Study: 1607733
Drug: HCR therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCR therapy (hyperthermo-chemoradiotherapy)
Study: 1607733
Drug: CR therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR therapy (chemoradiotherapy without hyperthermia)
Study: 3885454
Drug: Tinidazole (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (1600 mg) and Doxycycline (400 mg)
Study: 3885454
Drug: Tinidazole (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (1600 mg) and Placebo
Study: 30290817
Drug: Cisplatin‐etoposide chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin‐etoposide chemotherapy (maximum of six cycles)
Study: 24865132
Drug: linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin 5 mg once a day
Study: 22583605
Drug: Whole-pelvic external-beam
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-pelvic external-beam radiation therapy of 50 Gy/25 fractions and high-dose-rate intracavitary brachytherapy of 24 Gy/4 fractions without chemotherapy
Study: 18316519
Drug: ST-246 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST-246 (500 mg, 1,000 mg, 2,000 mg for fasting; 1,000 mg for nonfasting)
Study: 12727125
Drug: Panic control
Normalized name: BENZALKONIUM CHLORIDE 1 g in 59 mL TOPICAL GEL [Donut Panic Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panic control treatment
Study: 10975629
Drug: Control treatments,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatments, n = 65
Study: 1439854
Drug: Yohimbine (YOH)
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (YOH) ointment, 5 mg applied twice daily at the balanopreputial sulcus.
Study: 1439854
Drug: Papaverine delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaverine delivered with cavernous bodies by a Controlled Transdermal Drugs Administration System (C.T.D.A.S.).
Study: 24304605
Drug: Krill oil
Normalized name: Krill oil
DrugBank: Krill oil (DB16615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krill oil (600 mg of n-3 PUFA)
Study: 24304605
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (600 mg of n-3 PUFA)
Study: 21423000
Drug: Enteral fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral fish oil (9.75 g eicosapentaenoic acid and 6.75 g docosahexanoic acid daily)
Study: 18176174
Drug: Calcitriol administration
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol administration during 1 year
Study: 14563500
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal remedy (four tablets, three times a day for 30 days)
Study: 14563500
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical tablets, three times a day for 30 days)
Study: 1684310
Drug: Haloperidol decanoate
Normalized name: Haloperidol Decanoate
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol decanoate (HD), 60 mg every 4 weeks
Study: 31261577
Drug: Rational Emotive
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rational Emotive Behavior Therapy (REBT) intervention
Study: 19408821
Drug: Individual oral
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual oral hygiene instruction
Study: 19408821
Drug: Group oral
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group oral hygiene instruction
Study: 19408821
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of individual and group oral hygiene instructions
Study: 19408821
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral hygiene instruction (Control group)
Study: 17696684
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum (4 mg) after pretreatment with placebo
Study: 17696684
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum (4 mg) after pretreatment with 50 mg naltrexone
Study: 15167602
Drug: FTY720 (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 (0.25 to 3.5 mg, single oral dose)
Study: 9713029
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation (25 mg/kg/d)
Study: 7474673
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate as the sole phosphate-binding agent during sodium citrate infusion.
Study: 7474673
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate as the sole phosphate-binding agent during calcium infusion.
Study: 2128881
Drug: FSH (follicle-stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSH (follicle-stimulating hormone)
Study: 29057579
Drug: 6 weeks
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 weeks of daily Internet gaming (training group)
Study: 25881639
Drug: Massage treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage treatment combined with topical cactus and aloe cold compresses
Study: 25881639
Drug: Massage treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage treatment or cactus and aloe cold compresses alone
Study: 25139884
Drug: Increased serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased serum calcium levels during follow-up (higher tertile of change: 0.52 ± 0.13 mg/dL)
Study: 17883462
Drug: Azithromycin plus
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin plus loperamide (500 mg)
Study: 17883462
Drug: Azithromycin alone
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin alone (500 mg or 1000 mg)
Study: 14744822
Drug: Standard augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard augmentation (amniotomy and intravenous oxytocin)
Study: 14744822
Drug: Standard augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard augmentation
Study: 7656936
Drug: Budesonide (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (1.2 mg) once daily via a Nebuhaler for 6 months
Study: 21463380
Drug: No surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No surface treatment (control group)
Study: 17042769
Drug: G‐CSF administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF administration from day +5 (arm A)
Study: 17042769
Drug: Delayed, individually
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed, individually determined G‐CSF administration (arm B)
Study: 17042769
Drug: G‐CSF (arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (arm A and B)
Study: 11425416
Drug: MF59 adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59 adjuvanted vaccine (7.5 microg doses)
Study: 11425416
Drug: Non-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted vaccine (30 microg doses)
Study: 11425416
Drug: MF59 adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59 adjuvanted vaccine (30 microg doses)
Study: 11425416
Drug: MF59 adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59 adjuvanted vaccine
Study: 9246960
Drug: Single-dose of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose of 1.2 g Augmentin at induction of anesthesia
Study: 28854884
Drug: Optimization program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimization program of drug prescribing consisting of a clinical medication review by a pharmacist, in collaboration with specialist physician of the geriatric/memory center and the referent physician.
Study: 25277272
Drug: Continuous androgen
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous androgen deprivation therapy (ADT) with docetaxel
Study: 25277272
Drug: Continuous androgen
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous androgen deprivation therapy (ADT) without docetaxel
Study: 24100934
Drug: Financial incentives
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Financial incentives of £15 (€17; $22) for each depot injection over a 12 month period
Study: 11071030
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with posterior capsule rupture with or without vitreous loss (PCR +/‐ VL), n=192
Study: 7906190
Drug: Lamotrigine 100
Normalized name: lamotrigine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine 100 mg oral daily
Study: 3307890
Drug: Chlorpheniramine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine plus cimetidine 400 mg q.d.s. (21 patients)
Study: 28692641
Drug: Amoxicillin clavulanate
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin clavulanate (oral) for 7 days
Study: 23430708
Drug: Individual counseling
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual counseling plus nicotine replacement treatment (NRT)
Study: 23430708
Drug: Computer-based Internet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-based Internet smoking treatment plus NRT
Study: 21958958
Drug: Paracetamol (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (12 mg/kg single dose)
Study: 21958958
Drug: Ketoprofen lysine
Normalized name: ketoprofen lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen lysine salt (40 mg, open-label)
Study: 18436083
Drug: Randomized treatment
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized treatment group (blood pressure goal or antihypertensive drug)
Study: 16611714
Drug: Heavy aspirin
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy aspirin ingestion
Study: 16611714
Drug: Total analgesic
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total analgesic ingestion > or =0.3 kg/yr
Study: 12893983
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg sibutramine vs. placebo in CC genotype carriers
Study: 8871138
Drug: Ibuprofen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (10 mg/kg, n = 71)
Study: 8871138
Drug: Acetaminophen (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (n = 73)
Study: 21227460
Drug: L-D (use
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-D (use of laparoscopic instruments with direct vision)
Study: 21227460
Drug: L-V (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-V (standard laparoscopic suturing and knot tying)
Study: 20117252
Drug: Oral furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral furosemide (40mg)
Study: 20117252
Drug: Furosemide +
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide + oral volume replacement (F+R)
Study: 15780739
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose (40 microg) of recombinant hepatitis B vaccine
Study: 15780739
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (20 microg) of recombinant hepatitis B vaccine
Study: 15780739
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose (40 microg) for patients with CD4 cell counts > or = 350 cells/mm3
Study: 15780739
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (20 microg) for patients with CD4 cell counts > or = 350 cells/mm3
Study: 15780739
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose (40 microg) for patients with CD4 cell counts < 350 cells/mm3
Study: 15780739
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (20 microg) for patients with CD4 cell counts < 350 cells/mm3
Study: 15780739
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose (40 microg) for patients with HIV viral load < 10,000 copies/mL
Study: 15780739
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (20 microg) for patients with HIV viral load < 10,000 copies/mL
Study: 15780739
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose (40 microg) for patients with HIV viral load > or = 10,000 copies/mL
Study: 15780739
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (20 microg) for patients with HIV viral load > or = 10,000 copies/mL
Study: 11919486
Drug: NVP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVP plus zidovudine (twice daily for 1 week)
Study: 11919486
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose NVP alone
Study: 7438350
Drug: Antiheart antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiheart antibody (AHA)
Study: 7438350
Drug: Antiviral antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral antibody (AVA)
Study: 7438350
Drug: Antiviral response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Antiviral response to viral infections
Study: 28504921
Drug: Plasminogen Activator
Normalized name: Plasminogen activator
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plasminogen Activator Inhibitor-1 (PAI-1)
Study: 28504921
Drug: Homeostatic model
Normalized name: collagen hemostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeostatic model assessment of insulin resistance
Study: 19446890
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg daily, p.o.)
Study: 17254831
Drug: Vaccine uptake
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine uptake among students with younger, male, or not literate family heads.
Study: 17254831
Drug: Vaccine uptake
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine uptake among students from households with higher per-capita income.
Study: 15658548
Drug: Vitrum osteomag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitrum osteomag (2 tablets daily for 12 months)